News Releases

Wednesday, July 01, 2015

Sujana Biotech, a new biotech start-up, is launched by BioMotiv

CLEVELAND – BioMotiv, LLC (“BioMotiv”) a drug development accelerator associated with The Harrington Project for Discovery & Development – centered at University Hospitals in Cleveland, Ohio – announces the formation of Sujana Biotech, LLC, (“Sujana Biotech”) a company developing novel technologies and therapeutic products for a range of inflammatory and vascular disorders. 

The technology, licensed from Case Western Reserve University, is based on seminal research by scientific founders Daniel Simon, MD, President, University Hospitals Harrington Heart & Vascular Institute, and Herman K. Hellerstein, Chair of Cardiovascular Research and Professor of Medicine, Case Western Reserve University School of Medicine, Edward Plow, PhD, Chair of the Department of Molecular Cardiology, and Robert C. Tarazi, MD, Endowed Chair in Heart and Hypertension Research, Cleveland Clinic, and Yunmei Wang, PhD, Research Scientist and Assistant Professor of Medicine, Case Western Reserve University School of Medicine.  These scientists identified a unique binding site on the leukocyte integrin Mac-1 that is responsible for the pathologic recruitment and activation of leukocytes at sites of vascular injury.


Monday, June 29, 2015

Mevion Medical Systems delivers proton accelerator to Seidman Cancer Center at University Hospitals

CLEVELAND – Mevion Medical Systems is annoucing the delivery of the superconducting synchrocyclotron accelerator for its MEVION S250 proton therapy system under installation at University Hospitals (UH) Seidman Cancer Center and UH Rainbow Babies & Children’s Hospital in Cleveland.

The accelerator, which is the core of the proton therapy system, was delivered Friday. Its installation is a crucial step in the deployment of the proton therapy system at UH. The unit will be the first proton therapy system in Ohio treating adult and pediatric cancer patients when it begins clinical operation in the spring of next year. This is the sixth accelerator delivery for Mevion, the innovator behind the world’s most efficient and cost-effective high-precision proton therapy system.


Friday, June 19, 2015

University Hospitals grows concussion management program with primary care specialists and physical therapists

CLEVELAND – In an effort to enhance care of concussions throughout Northeast Ohio, University Hospitals has developed a system-wide program involving specialists from the Neurological Institute and Sports Medicine program working together with primary care physicians.

“We want to provide physicians and patients with the gold standard of care and management,” Susannah Briskin, MD, Co-Director of the UH Concussion Management Program, a pediatric sports medicine physician with UH Rainbow Babies & Children’s Hospital, and Assistant Professor of Pediatrics at Case Western Reserve University School of Medicine.


Thursday, June 18, 2015

First patient from China implanted with diaphragm pacing system at University Hospitals

CLEVELAND – Yichang Li became the first patient from China to be implanted with the diaphragm pacing system (DPS).  Mr. Li suffered a spinal cord injury in a car accident that left him quadriplegic four years ago.  He is shown here a week after surgery with his wife Jiang Cui Ping and Ray Onders, MD, who implanted the DPS at University Hospitals Case Medical Center on June 5. 

Dr. Onders is a co-inventor of DPS and Director, Adult Minimally Invasive Surgery at UH.  The system allows spinal-cord injured patients to breathe without a ventilator by electronically stimulating their diaphragm muscle. The system also has been successful with ALS patients. Dr. Onders, who is also a Professor of Surgery at Case Western Reserve University School of Medicine, recently began a study for its use in intensive care unit patients. 


Thursday, June 11, 2015

New England Journal study with Dr. Andrew Sloan from UH Case Medical Center discovers new method of classifying low-grade brain tumors

CLEVELAND – A Case Comprehensive Cancer Center (CCCC) brain surgeon and neurosurgery professor is among the primary authors of a new approach to classifying tumors that could lead to significant improvements in their diagnosis and treatment. The research and recommendations appear online June 10 in The New England Journal of Medicine.
 
Andrew Sloan, MD, Director of the Brain Tumor and Neuro-Oncology Center at University Hospitals Case Medical Center, said the new classification system has the potential to provide far more accurate assessments of brain tumors known as low and intermediate grade gliomas (LGGs) – which in turn could enhance patients’ outcomes.
 
Scientists and physicians from Cleveland and 43 other federally designated cancer centers used molecular and genetic analysis to develop an approach that reduces the role of individual observers’ assessments of the tumors’ appearance. 



You must be logged in to view this item.



Login

This area is reserved for members of the news media. If you qualify, please update your user profile and check the box marked "Check here to register as an accredited member of the news media". Please include any notes in the "Supporting information for media credentials" box. We will notify you of your status via e-mail in one business day.